Introduction: Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, and relatively chemoresistant and radioresistant malignancy with limited therapeutic options. Our objective was to investigate the prevalence of programmed death ligand 1 (PD-L1) and the characteristics of the immune environment in this disease.
Introduction
Malignant pleural mesothelioma (MPM) is a rare, highly aggressive malignancy of the mesothelium that is usually diagnosed at an advanced stage, and chemotherapy, which is the only available therapeutic option in this setting, is modestly effective. 1 The overall prognosis of advanced stage MPM is poor, with a median survival of less than 12 months and a 5-year survival rate of less than 5%. The standard of care consists of a combination of cisplatin and pemetrexed that prolongs median survival time by approximately 3 months. 2 Disappointingly, there is no approved agent for second-line treatment of MPM. 3 In this rare malignancy, the proposed prognostic factors include clinical variables, radiological parameters at presentation, and pathological/molecular findings; however, the vast majority of them are not fully validated. 4 Histologic type remains one of the most reliable prognostic factors because the epithelioid subtype is associated with better prognosis and the sarcomatoid subtype with the worst. 5 Although, some biomarkers such as thymidylate synthase have been proposed as a predictor of sensitivity to pemetrexed, 6 reliable prognostic biomarkers are still missing in MPM. Additionally, a personalized therapeutic approach is urgently needed.
The genetic landscape in MPMs has been characterized in a number of studies. The genomic background of MPM shows recurrent somatic mutations in a number of tumor suppressor genes (i.e., cyclin-dependent kinase inhibitor 2A gene [CDKN2A], neurofibromin 2 (merlin) gene [NF2] , and BRCA1 associated protein 1 gene [BAP1]). Additional gene alterations include several pathways (for example, the cell cycle, DNA repair, mitogen-activated protein kinase, and phosphoinisitide-3-kinase/AKT pathways). [7] [8] [9] In preclinical models of primary or commercially available MPM cell lines, transcriptome and metabolic profiles have been found to be highly variable. 10 Marked genomic instability was observed from MPM tissue, and the interpatient variability was confirmed by the observation of multiple p53 isoforms in primary cell lines established from MPM tissue. These findings are consistent with the tumor protein p53 gene (TP53) being rarely inactivated in MPM. 11 On the whole, however, frequencies of protein-altering somatic mutations are much lower than in other cancer types. 8 Gene expression profiling and microRNAs (miRNAs) have also been explored to some extent. A study investigating MPM examined the molecular basis of the histological subtypes. 8 They showed that the epithelioid subtype up-regulated markers of primary mesothelial cells and the sarcomatoid subtype upregulated markers of epithelial-to-mesenchymal transition. Another study investigated DNA damage repair genes 12 ), were prognostic for survival. Several miRNAs controlling TP53 and CDKN2A gene expression were shown to be down-regulated in a set of MDM2 protooncogene-positive mesotheliomas, suggesting a potential role of miRNA in MPM growth. 13 Reactivating immune responses that are silenced by immune checkpoints have recently gained a lot of interest. Checkpoint blockade has already shown promising preclinical and clinical results in several cancer types and is currently also being investigated in MPM.
14 Programmed cell death 1 (PD-1) is a receptor present on activated T cells that mediates immunosuppression in which the PD-1 ligands programmed death ligand 1 (PD-L1) and programmed death ligand 2 share an immunosuppressive activity and may be produced by either tumor cells (TCs) or stromal/tumor-infiltrating immune cells (ICs). 15 In clinical trials, PD-1-or PD-L1-blocking antibodies were associated with response in up to 50% of several human cancers, including metastatic melanoma, NSCLC, renal cell carcinoma, head and neck carcinoma, and bladder carcinoma, [16] [17] [18] [19] [20] [21] [22] with an enriched, but not exclusive, response rate in PD-L1-positive tumor. To date, the role of PD-L1 in predicting response to specific targeted treatments is incompletely understood. In a recent meta-analysis, a higher response of PD-L1-positive tumors (compared with PD-L1-negative ones) was reported for melanomas (45% versus 27%) and NSCLC (29% versus 11%). 15 However, the treatment efficacy had also been observed in PD-L1-negative patients, 23 thus suggesting that other biomarkers in addition to PD-L1 may be needed to identify all patients potentially benefiting from PD-L1/PD-1 blockade. 21, 23 Although some data on PD-L1 expression in MPM [24] [25] [26] indicate that PD-L1 is more highly expressed by sarcomatoid than epithelioid MPMs, there are few data to understand the tumor and immune microenvironment in MPM.
In this retrospective study, cases of MPM with clinical annotates and known mutational status were analyzed for their immune gene expression profile as detected by NanoString technology along with PD-L1 expression levels in tumor and associated ICs with the aim of generating knowledge about correlation between immune microenvironment and checkpoint expression status.
Materials and Methods

Patient Characteristics and Tumor Samples
A total of 99 biopsy samples were selected at the San Luigi University Hospital (Orbassano, Turin, Italy) and Saint Antonio and Biagio General Hospital (Alessandria, Italy) from a previous series of 123 consecutive MPM cases; detailed clinical data and mutational profile were determined by next-generation sequencing, as previously reported. 27 The available formalin-fixed paraffin-embedded (FFPE) tissue samples were obtained by pleuroscopy or video thoracoscopy in patients with stage III and IV MPM, all treated with platinum-based plus pemetrexed chemotherapy. None of the patients received an operation or radiation therapy at any time. All samples were reviewed and classified according to the current WHO classification. 5 After revision of the tumor type and neoplastic cell content (by authors L.R. and M.P.) from the available FFPE tissue samples, two hematoxylin and eosin-stained slides (first and last cut section) and eight freshly cut whole sections were sent for RNA and immunohistochemistry (IHC) analysis (four with a thickness of 7 mm for RNA isolation and the other four with a thickness of 4 mm for IHC). Two further serial sections were retained for parallel IHC stains at the San Luigi Hospital pathology laboratory. Before management of the tissue blocks and slides, all samples were deidentified and all cases anonymized by a pathology staff member not involved in this project. Only coded slides were used throughout the study. Informed consent was obtained from each patient, and the institutional review board of the institution approved the study.
Immunohistochemistry
For the purpose of comparing the PD-L1 IHC performance and, above all, the scoring procedure between different centers, the immunostaining was performed in two independent pathology laboratories at the San Luigi University Hospital in Turin and at Genentech laboratories in South San Francisco, California. A standard in vitro diagnostic antibody clone and detection kit on a standard autostainer platform and standard testing protocols were used for immunohistochemistry.
The same PD-L1 antibody batch (clone SP-142 [Genentech/Ventana Roche]) and the same staining procedure were used. In particular, an automated immunostainer (Benchmark [Ventana, Tucson, AZ]) was used with the primary PD-L1 antibody diluted 1:30, followed by the appropriate detection kit and hematoxylin nuclear counterstain. Positive controls were represented by human placental tissue, and negative controls were run with omission of the primary antibody.
In selected cases with additionally available leftover tissue, PD-L1 expression results were further validated by using another PD-L1 antibody (SP-263) on the same diagnostic platform (Benchmark, Ventana), with the analysis performed in the pathology laboratory at San Luigi Hospital. Moreover, to validate immune gene expression results in the same selected cases with leftover tissue, immunostainings were also performed to assess T-cell (CD3, CD4, and CD8) and B-cell (CD20) antigens associated with inflammation. Seven of the nine cases in group 3 and 20 of the 43 cases in group 2 were tested.
Scoring of PD-L1 Immunostaining
The PD-L1 scoring with SP142 was performed as previously described. 21 Two trained pathologists (M.P. and H.K.) and one local pathologist (L.R.) at the two sites screened all PD-L1 reactions obtained in their respective laboratory (authors L.R. and M.P. in Turin and H.K. in California). For discordant scores, consensus scoring was used.
As published before, PD-L1 reactivity in TCs and ICs was scored separately. 21 Briefly, PD-L1 expression was scored by IHC in TCs (percentage of PD-L1-expressing TCs scored as TC3 !50%, TC2 !5% to <50%, TC1 !1% to <5%, and TC0 <1%) and in tumor infiltrating ICs (percentage of tumor area scored as IC3 !10%, IC2 !5% to <10%, IC1 !1% to <5%, and IC0 <1%). A membrane staining was considered positive if detected in 1% of cells; the extent of this reactivity was recorded as a percentage of both tumor-positive and immunopositive cells compared with the total area of either the tumoral component (excluding necrotic and fibrotic areas) or the IC intratumoral infiltrates (excluding extratumoral lymphocytes and macrophages), respectively.
IHC results with SP-263 antibody were scored in Turin (by M.P. and L.R.) by using the same criteria as described earlier in this article.
RNA Isolation and Gene Expression Analysis
RNA was extracted from FFPE tissue sections (four sections, each 7 mm thick) by using the RNeasy FFPE kit (Qiagen, Hilden, Germany). RNA was quantified with the Thermo Scientific Nanodrop 8000 (Thermo Fisher Scientific, Wilmington, DE).
Details of the nCounter technology (NanoString Technologies, Seattle, WA) have been previously reported. 28 Briefly, code sets for 805 genes associated with cancer and immune response biology were obtained from NanoString Technologies. Each probe in the code set is manufactured with specificity to a 100-base region of the target mRNA of interest and linked to a biotinylated capture probe. Also included is a complementary reporter probe tagged with a specific fluorescent barcode, thus resulting in two sequence-specific probes for each target transcript. Probes were hybridized to 500 ng of total RNA for 20 hours at 65 o C and applied to the nCounter preparation station for automated removal of excess probe and immobilization of probe-transcript complexes on a streptavidin-coated cartridge. Data were collected with the nCounter digital analyzer by counting the individual barcodes.
Analysis and normalization of the raw NanoString data was conducted with nSolver Analysis Software v2.0 (NanoString Technologies). Raw counts were normalized to internal levels of four reference genes: TATA-box binding protein gene (TBP); tubulin beta class I gene (TUBB); transmembrane protein 55B gene (TMEM55B); and VPS33B, late endosome and lysosome associated gene (VPS33B). Normalized data was log2-transformed, median-normalized, and then used as input for further analysis.
The genes with variance greater than 1 (n ¼ 400) were selected for unsupervised hierarchical clustering analysis by using the Spearman rank correlation and ward D2 agglomeration method by using the R Bioconductor package ComplexHeatmap. Cox proportional hazards analysis to correlate gene expression with overall survival (OS) was performed by using the R Bioconductor package Survival. A separate differential analysis of patients with more than 12 months survival as compared with less than 6 months was performed with the R Bioconductor package Limma. Kaplan-Meier (KM) plots of selected genes were generated by using the Survminer package in R.
Results
Patients and Pathology
The 99 cases included 75 epithelioid and four sarcomatoid mesotheliomas, with the remaining 20 cases classified as biphasic tumors. All cases matched the expected IHC profile, with expression of calretinin and at least one of the following markers: cytokeratin 5/6 and/ or D2-40 and/or Wilms tumor protein 1 in the absence of reactivity for carcinoembryonic antigen and BerEP-4 (known markers of adenocarcinomas). The median age at diagnosis was 67 years (range 46-82) with a male-tofemale ratio of 2:1. Of the 93 patients for whom smoking status was available, 47 (50.5%) were current smokers and 46 (49.5%) were former or nonsmokers. Asbestos exposure was reported in 42 of the 79 patients for whom this information was available (53%). After a mean follow-up of 20.7 months (range 3-130), 86 of 99 patients had died of their disease.
Immunohistochemistry for PD-L1
PD-L1 (SP-142) IHC performed in two laboratories showed a complete concordance in most of the samples (93%). For the remaining 7% of cases with discrepant scores, an average value of the IHC percentage-positive scores from the two laboratories was used for estimating the final PD-L1 status and prevalence. The criteria considered were intensity of cell membrane reactivity, including weak TC staining as positive and excluding intratumoral macrophages in the TC score. Specific membrane staining of atypical stromal cells was interpreted as sarcomatous/biphasic MPM, and the tumor area was restricted to viable cells excluding necrotic and fibrotic areas, ensuring accurate determination of the percentage of positive TCs (Fig. 1) .
On the basis of the aforementioned criteria, 14% of the MPM cases were PD-L1 TC-positive according to a reactivity threshold higher than 1% positive on TCs (Table 1 ). In particular, the results of testing for PD-L1 were positive for the TCs of 14 cases, including five with reactivity of less than 5% (scored TC1), seven with reactivity between 5% and 50% (TC2), and two with reactivity of more than 50% (TC3). With respect to the ICs (including intratumoral lymphocytes and macrophages), there were 10 positive cases as follows: five with reactivity of 5% (score IC1); three with reactivity between 5% and 10% (IC2); and two with reactivity greater than 10% (IC3). PD-L1 expression in ICs was generally observed in cases with reactivity on TCs. Further, we observed that in eight cases PD-L1 was expressed in both TCs and ICs (with variable scores), whereas the remaining six TC-positive cases had no PD-L1 reactivity in ICs. Taking the TC and IC scores together, 16% of MPM cases were PD-L1-positive (>1%).
The group of PD-L1 IHC-positive tumors was enriched in biphasic and sarcomatoid histotypes of MPM. Of the 14 TC-positive cases, five were of the epithelioid type compared with eight biphasic MPMs and one 
No statistically significant differences were observed between PD-L1-positive and PD-L1-negative MPMs in relation to patient demographics (age and sex) or asbestos exposure. Significant correlations were found between PD-L1 IHC positivity and smoking habit (Fisher's test, p ¼ 0.01) and between PD-L1 IHC-positive cases and a worse outcome (10.7 versus 18.1 months) (hazard ratio ¼ 1.69, 95% confidence interval [95% CI]: 1.16-2.22, KM p < 0.0001) (Fig. 2) .
To validate the IHC results, samples from 30 cases with leftover tissue were stained with SP-263 clone (21 TC0 cases and 9 TC1, TC2, or TC3 cases). Among the TC0 cases only two of 21 showed less than 1% of positivity in TCs but not in ICs. Among the positive cases a higher intensity of expression was detected with the SP-263 in all cases, but with comparable percentages of positive cells. In summary, SP-142 staining showed a mean percentage expression of 14%, ranging from 1.5% to 65%, whereas SP-263 staining showed a mean of 29%, ranging from 4% to 85% positivity, without changes in TC categories. Conversely for ICs, comparable staining in terms of positive cells and intensity was detected for the two antibodies.
Cancer and Immune Gene Expression Analysis
To better characterize the tumor immune microenvironment in MPM, gene expression profiles were analyzed by using an immune cancer gene panel of more than 800 genes in 87 tumor cases. Patient demographics in terms of age, sex, and smoking status were comparable to that of the overall series studied by IHC (Supplementary Table 1 ).
On the basis of unsupervised cluster analysis of the gene expression data using a Spearman correlation, MPM cases were classified into three molecular subgroups representing different immune profiles: group 1 comprised 40% of the samples (n ¼ 35), group 2 contained 49% (n ¼ 43), and group 3 had 10% (n ¼ 9). As the heat map shows, the differentiating feature was that groups 2 and 3 that showed high expression of genes associated with an adaptive immune response including T cell-and B cell-related genes (Fig. 3) . Group 2 showed higher relative expression of B-cell and antigen presentation-related genes (such as cluster of differentiation-79A CD 19 molecule gene, membrane spanning 4-domains A1, and histocompatibility antigen-DO) and lower expression of T-cell genes when compared with group 3 ( Supplementary Fig. 1) . Notably, the B-cell enrichment did not correlate with enhanced major histocompatibility class II antigen presentation or with major histocompatibility class I antigen-processing genes in this group (see Supplementary Fig. 1 (Supplementary Fig. 2 ). High expression of most of the immune-related genes in the vast majority TC  IC  TC or IC   TC3  2%  IC3  2%  TC3 or IC3  3%  TC2/3  9%  IC2/3  5%  TC2/3 or IC2/3  10%  TC1/2/3  14%  IC1/2/3  10%  TC1/2/3 or IC1/2/3  16% IC and TC staining was scored as reported previously for SP142 IHC. 21 Briefly, TC3 indicates a level of 50% or more, TC2 indicates a level from at least 5% to less than 50%, TC1 indicates a level form at least 1% to less than 5%, IC3 indicates a level of 10% or more, IC2 indicates a level from at least 5% to less than 10%, and IC1 indicates a level from at least 1% to less than 5%. PD-L1, programmed death ligand 1; IHC, immunohistochemistry; TC, tumor cell; IC, immune cell. (w60%) of analyzed cases, as observed in groups 2 and 3, suggested that MPM is represented by a highly inflamed cancer type.
IHC correlative investigation showed a high expression of CD3-positive T-infiltrating lymphocytes in all evaluated cases of group 3, with a similar amount of CD4þ/CD8þ T cells in both PD-L1-positive and PD-L1-negative cases (Supplementary Fig. 3 ).
In 20 of 43 selected cases of group 2, IHC for ICs showed the presence of a high amount of CD20-positive B lymphocytes (see Supplementary Fig. 3 ) in all but one case (95%), as suggested by the presence in this group of a higher level of follicular chronic inflammation as a morphological hallmark (Supplementary Table 2 ).
On the other hand, group 1 is mainly represented by "immune deserts," with little evidence of B-cell and T-cell infiltration, and it was enriched in the sarcomatoid and biphasic histologic type of MPM (Fig. 4C) Supplementary  Fig. 1 ). This group also showed higher expression of cell proliferating and tumor growth promoting genes. High-PD-L1 mRNA showed a trend of slightly worse prognosis of OS and progression-free survival (PFS) when a median cutoff for gene expression was used (data not shown). The hazard ratios of PD-L1 mRNA with a median split were 1.24 (95% CI: 0.81-1.91) for PFS and 1.52 (95% CI: 0.99-2.34) for OS. PD-L1 expression was highly expressed in group 3 both by RNA (p ¼ 2 Â 10 À05 ) and by IHC ( Fig. 4A and B) . Most of the TC2/IC2-and TC3/IC3-positive cases were restricted to group 3. The relative prognostic associations for OS of the different groups are shown in Fig. 4D . Group 3 showed a trend toward poor prognosis, and groups 1 and 2 had the same median survival times, with group 1 slightly outperforming group 2. Given the study size limitation, none of the associations were statistically significant (p ¼ 0.37).
Molecular and Clinicopathological Correlation
A detailed morphological analysis (see Supplementary Table 2 ) was performed in the 87 cases with gene expression data, and clinicopathological characteristics were analyzed according to immunerelated gene profile groups. As a whole, the major clinicopathological characteristics, including age, sex, asbestos exposure, smoking habit, and histological type, had no significantly different distribution among the three groups.
Notably, group 3 included MPM cases with higher nuclear (chi-square, p ¼ 0.04) and cellular atypia (chisquare, p ¼ 0.03), with presence of necrosis (chi-square, p ¼ 0.02) and high mean mitotic count (chi-square, p ¼ 0.04). Group 2 showed chronic inflammation either in follicles (21%) or as single scattered cells (60%). A borderline statistical significance was found for the distribution of stromal cellularity (chi-square, p ¼ 0.06) and chronic inflammation (chi-square, p ¼ 0.05) among the three groups (see Supplementary Table 2) . No other specific morphologic characteristics showed significant differences among the three groups.
Prognostic Markers
To investigate genes correlated with OS or PFS, we performed two analyses: an unsupervised differential gene expression analysis comparing patients with MPM who survived less than 6 months (n ¼ 43) with those who survived more than 12 months (n ¼ 47) and a Cox proportional hazards analysis of survival of the expression from the most variant genes. The top 20 genes that were most significant from both analyses are shown in Supplementary Table 3 . With regard to these top genes from each of these analyses, we searched the literature for prognostic biomarker relevance to mesothelioma or lung cancer and selected C-X-C motif chemokine ligand 10, hyaluronan-mediated motility receptor, and ribonucleotide reductase regulatory subunit M2. The KM plots of these genes show the p value associated with log-rank test value with use of a median split (not the p value on the basis of which they were selected). High expression of C-X-C motif chemokine ligand 10 gene (CXCL10), hyaluronan mediated motility receptor gene (HMMR), and ribonucleotide reductase regulatory subunit M2 gene (RRM2) was associated with worse OS (Supplementary Fig. 4 ).
Discussion
A better understanding of the molecular pathogenic changes of MPM is critically needed to develop more effective approaches for identifying and treating this devastating disease. Chronic inflammation triggered by asbestos exposure leads to increased production of free radicals and reactive oxygen species from inflammatory cells and/or to alteration of immunocompetent cells and later reduction of tumor immunity. 29, 30 MPM is thought to have a variable degree of infiltrating T-regulatory cells and M2 macrophages, which are believed to facilitate tumor evasion from the host immune system. Additional immunosuppressive factors identified in other human tumor types, such as tumor-associated PD-L1 expression, may be relevant in MPM. 31 Despite initial studies investigating the activity of anti-PD-1 and anti-PD-L1 monoclonal antibodies, 24, 25, 32 PD-L1 prevalence in this disease is still poorly investigated.
Genomic-based approaches have significantly improved our understanding of response and resistance to immunotherapy in general and to immune checkpoint blockade. Both somatic-and germline-positive correlates of response identified high mutational/neoantigen load and low intratumoral heterogeneity. 33 In MPM, there is consistent evidence that the mutational load is generally extremely low. 8, 11, 27, 34 A comprehensive genomic analysis using DNA and RNA from 216 fresh frozen specimens of human MPMs demonstrated a low protein-altering mutation rate compared with that in other cancers. 8 In that study, the molecular profiling showed that the sarcomatoid MPM subgroup had higher PD-L1 RNA expression. In the current study, we have explored and classified MPMs on the basis of PD-L1 protein expression by IHC and their tumor microenvironment by using immune-related gene expression patterns.
In the current study, PD-L1 was detected by IHC in TCs or ICs in 16% of cases, with a significantly higher expression in sarcomatoid and biphasic MPM than in the epithelial subtype, which is in agreement with supporting data from the literature, as already summarized. These findings were obtained by using a PD-L1 antibody (SP142) that targets the intracellular domain of the ligand expressed on the TC membrane and is known to also stain the IC population, including intratumoral lymphocytes and macrophages. It can be hypothesized that a malignant neoplasm with a marked "inflamed" phenotype is worthy of investigation in both cell populations, with use of strict criteria to provide a reliable percentage of positive TCs and also of ICs. Regarding the TCs, in our experience, it is crucial to accurately define the "denominator" (namely, how to select the MPM tumor area that contains viable neoplastic cells, accurately excluding necrotic and fibrotic areas). This enriches the PD-L1-positive cell fraction. Regarding the ICs to be scored, we included lymphocytes and macrophages that are strictly confined within the TC area. With this framework, the extent of reactive ICs was relatively limited in the current series, being detected in only 10 cases (10%) and generally in restricted areas (the most common scores were IC1 and IC2). In the context of TC, 14 cases had some reactivity in more than 1% of cells, but only two cases exceeded the threshold of 50%, which has been suggested to be a predictive value of response to pembrolizumab. The other positive cases were scored TC1 or TC2, with the reactivity ranging from 1% to 15% only. These distributions are in line with the scant reported data on PD-L1 expression in MPM, although they were obtained with different antibodies that have a variable affinity for the PD-L1 antigen. 21, 24 On the basis of the gene expression profile from an 800-gene panel, MPMs were classified into three groups. Of these, group 1 has the most immunologically ignorant or desert-like phenotype, with poor IC gene expression. 35 From a morphological point of view, this group was characterized by a hypercellular stroma with scant atypias and more scattered chronic inflammation. Given that this group has a strong stromal signature; we speculate that group 1 may need a combination treatment approach to enhance IC infiltration in these tumors.
Group 2 had moderate expression of T-cell effector genes and high expression of B-cell genes. Because increased B-cell expression was not correlated with increased antigen presentation genes, we believe that these B cells may be part of the adaptive cytotoxic response. An essential cytotoxic role for B cells was shown in preclinical mouse models of mesothelioma. 36 They showed that B cells are required for CD40-activated mesothelioma tumor regression. Thus, we hypothesize that patients with a group 2-like molecular signature could be candidates for a combination of B-and T-cell activation therapeutic strategies.
Group 3 was associated with high PD-L1 expression levels as compared with the other groups and a high expression of T effector cells, suggesting that this group would be the most responsive to PD-1 blockade. This group was also molecularly defined by high expression of stroma genes and morphologically characterized by significantly higher cellular atypia, higher mean mitotic count, and presence of necrosis.
Survival and differential analysis comparing the gene expression profiles of patients with relatively good OS with the profiles of patients with poor survival resulted in identification of a handful of genes that could be novel prognostic markers. High levels of chemokine CXCL10 (median >50%) predicted poor PFS and OS. Previous studies have shown that reduced C-X-C motif chemokine receptor 3 expression on CD4-positive T cells exposed to asbestos or derived from asbestos-exposed patients correlated with a high level of CXCL10 in plasma, 37 supporting a role for CXCL10 in MPM pathogenesis. In concordance with our findings regarding RRM2, several studies have identified a prognostic role for RRM2 in a related clinical indication (NSCLC). [38] [39] [40] Similarly, for HMMR, a prognostic role has been identified in NSCLC. 41 In conclusion, to our knowledge, these data represent a first analysis supporting the idea that a subset of MPM is characterized by increased PD-L1 expression and preexisting immunity, as measured by an expression of genes related to an inflamed status. 42, 43 These data make MPM an attractive candidate for cancer immunotherapeutic options, at the very least in a substantial subgroup of patients with high PD-L1 expression in this devastating neoplasm.
